DUBLIN, March 17, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/qgd2sr/global_antibody) has announced the addition of the "Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.
The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
Report scope
In Global Antibody Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in antibody dealmaking
Chapter 3 - Leading antibody deals
Chapter 4 - Most active antibody dealmakers
Chapter 5 - Antibody contracts dealmaking directory
Chapter 6 - Antibody dealmaking by technology type
Chapter 7 - Partnering resource center
For more information visit http://www.researchandmarkets.com/research/qgd2sr/global_antibody
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article